LONDON, May 23, 2012 /PRNewswire/ --
According to Cold Chain IQ findings, nearly 30% of individuals surveyed reported temperature excursions in 6% or more of their temperature sensitive pharmaceutical product. Temperature excursions of pharmaceutical products can not only result in product losses, but also endanger patient lives.
Cold Chain IQ presents a new report examining temperature excursions in the distribution chain for clinical and commercial products and leading strategies that the pharmaceutical industry is employing to improve the storage and handling of temperature sensitive products.
Cold Chain IQ, the online resource for the temperature controlled supply industry has published the state of the industry report "Operating a Global Temperature Controlled Supply Chain."
This definitive research report looks at technologies and strategies the industry is employing to leverage partnerships and streamline processes in supply chains of temperature sensitive products.
Over the past year Cold Chain IQ conducted interviews with over 100 experts from all stages of the pharmaceutical and medical distribution chain from logistics to quality assurance, regulators to manufacturers. In this report we share their key challenges and strategies to overcome these.
Contributors include global heads of cold chain and experts from Latin America IMF, Pfizer, Word Courier Group, Roche, Eli Lilly, Modality Solutions, AMAG, Merck, Exelsius Cold Chain, Novo Nordisk, DHL, MacroGenics, Laminar Medica, Logistics Institute of Asia Pacific and South African Refrigerated Distribution Association as well as unique perspective from 300+ global attendees from the 11th Annual Cool Chain Logistics Europe industry forum.
The 28 page report features in-depth insight on the rise of emerging markets, reverse logistics, the increased push towards eco initiatives, CRT and quality management systems as well as a detailed overview of the industry.<
Copyright©2010 PR Newswire.
All rights reserved